(Yicai Global) March 19 -- Beijing Infervision, a Chinese artificial intelligence start-up developing medical imaging technology, has raised CNY300 million (USD47 million) in B+ round financing, which will go to developing, producing and internationally marketing AI medical imaging products, online news outlet 36Kr reported.
Investors in the round include Xianghe Capital Co., Advantech Capital LP, Genesis Capital LLC, Sequoia Capital China, and Qiming Venture Partners.
Infervision's current diagnostic AI products for lung cancer are relatively mature and will gradually go into active use in hospitals after new features are added. The cerebral artery infarction program of the company's brain AI product line has also been applied in several cerebral stroke research centers. The company's AI-assisted cardiac screening, AI-assisted fracture screening, liver-related abdominal AI products, and AI-assisted breast cancer screening have also entered the test phase.
Infervision had deployed its AI systems in seven hospitals on Fudan University's Top 10 Hospitals List and partnered with half on the university's Top 50 Hospitals List, serving about 450,000 patients, company data show.
Infervision has launched operations in such major cities as Shanghai, Wuhan, Dalian, and Guangzhou last year to expand nationwide. It has also set up offices in the US, Japan and Germany and has installed its system in a hospital in Japan.